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Abstract: This randomized, double-blind, double-dummy, multicenter trial compared efficacy 
and safety of tramadol HCL 37.5 mg/paracetamol 325 mg combination tablet with tramadol 
HCL 50 mg capsule in the treatment of postoperative pain following ambulatory hand surgery 
with iv regional anesthesia. Patients received trial medication at admission, immediately after 
surgery, and every 6 hours after discharge until midnight of the first postoperative day. Analgesic 
efficacy was assessed by patients (n = 128 in each group, full analysis set) and recorded in a 
diary on the evening of surgery day and of the first postoperative day. They also documented 
the occurrence of adverse events. By the end of the first postoperative day, the proportion of 
treatment responders based on treatment satisfaction (primary efficacy variable) was comparable 
between the groups (78.1% combination, 71.9% tramadol; P = 0.24) and mean pain intensity 
(rated on a numerical scale from 0 = no pain to 10 = worst imaginable pain) had been reduced 
to 1.7 ± 2.0 for both groups. Under both treatments, twice as many patients experienced no pain 
(score = 0) on the first postoperative day compared to the day of surgery (35.9% vs 16.4% for 
tramadol/paracetamol and 36.7% vs 18% for tramadol treatment). Rescue medication leading 
to withdrawal (diclofenac 50 mg) was required by 17.2% patients with tramadol/paracetamol 
and 13.3% with tramadol. Adverse events (mainly nausea, dizziness, somnolence, vomiting, 
and increased sweating) occurred less frequently in patients under combination treatment 
(P = 0.004). Tramadol/paracetamol combination tablets provided comparable analgesic efficacy 
with a better safety profile to tramadol capsules in patients experiencing postoperative pain 
following ambulatory hand surgery.
Keywords: ambulatory hand surgery, analgesia, combination therapy, paracetamol, 
  postoperative pain, tramadol
Introduction
The development of minimally invasive surgical procedures and an improvement in 
anesthetic techniques have resulted in a continuous world-wide increase in ambula-
tory (outpatient) surgery.1,2 Although most ambulatory procedures are associated with 
relatively minor surgical trauma, severe postoperative pain can occur causing extreme 
discomfort, sleep deprivation and suffering3 which might delay discharge or cause 
unanticipated hospital admission, thereby increasing the burden for the patients as well 
as healthcare costs.4,5 The proportion of patients experiencing moderate to severe pain 
in the first 24 to 48 postoperative hours can reach 40%.6,7 Appropriate postoperative 
pain management is therefore indicated.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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In recent years, pain management has focused on the 
therapeutic potential of combining analgesic medications 
with complementary pharmacokinetic and pharmacodynamic 
profiles to achieve greater efficacy and a better safety profile 
than the individual agents.8,9 In the fixed-combination tablet 
tramadol HCL 37.5 mg/paracetamol 325 mg (Grünenthal 
GmbH, Aachen, Germany), the two individual compo-
nents have different mechanisms of action. Tramadol HCL 
  (Grünenthal GmbH), a centrally acting weak opioid agonist 
(with selectivity for the µ-receptor) and monoamine neu-
rotransmitter reuptake inhibitor, has been proven to provide 
sustained relief for moderate to severe postoperative pain for 
several types of surgery10 whereas paracetamol, a rapid-onset, 
nonopioid analgesic and antipyretic,11 is used for the man-
agement of mild to moderate pain. The combination tablet 
was proven efficacious in acute postoperative dental pain,12 
postoperative pain following orthopedic and abdominal 
surgery,13 fibromyalgia pain,14 low back pain,15–17 migraine 
pain,18 and as add-on therapy for osteoarthritis flare19 and 
rheumatoid arthritis pain.20 A detailed review of the use 
of fixed-dose tramadol/paracetamol in the management of 
moderate to severe pain has been published.21 In addition, it 
was suggested in a recent study that the combination tablet 
might be as effective as gabapentin in the treatment of painful 
diabetic neuropathy in patients with type 2 diabetes.22
Hand surgery is frequently performed on an outpatient 
basis. In many cases, regional anesthetic techniques includ-
ing brachial plexus or major nerve blocks with intravenous 
anesthesia are used,23,24 thereby avoiding complications 
observed with general anesthesia. However, postoperative 
pain management at home using either tramadol, metamizol, 
or paracetamol as single substances after ambulatory hand 
surgery has been shown to be inadequate for up to 40% of 
all patients in a controlled trial.25 The objective of the present 
trial was to compare efficacy and tolerability between the 
combination analgesic tramadol HCl 37.5 mg/paracetamol 
325 mg (tramadol/paracetamol) and tramadol HCL 50 mg 
(tramadol) monotherapy in the management of postoperative 
pain following ambulatory hand surgery.
Methods
Patients
Patients between 18 and 75 years of age in good physical 
health according to the American Society of Anesthesiologists 
scale (ASA stage I or II)26 were included if they presented 
with a pathological condition involving bony or ligamentous 
structures of the hand requiring surgical   intervention. Main 
exclusion criteria were intake of short-acting analgesics 
within 12 hours prior to surgery until the final visit (second 
postoperative day) except for oral diclofenac 50 mg for 
rescue and after 24:00 h of the second calendar day; intake 
of long-acting analgesics within 72 hours prior to surgery 
until the final visit; intake of monoamine oxidase inhibitors 
within 30 days prior to surgery until 72 hours after the final 
visit; serious psychiatric or neurologic disorders, in particular 
epilepsy; known hypersensitivity to tramadol, paracetamol, 
or nonsteroidal anti-inflammatory medication; and a risk in 
terms of precautions, warnings, and contraindications in the 
product monograph for tramadol, tramadol/paracetamol, or 
diclofenac. Pregnant or lactating females were not allowed 
to participate.
Medication for concomitant diseases could be taken 
provided the patient had been on a stable dose for 30 days 
prior to surgery. For the symptomatic treatment of nausea 
and vomiting metoclopramide 10 mg up to a maximum daily 
dose of 30 mg was recommended.
Trial design
This double-blind, double-dummy, randomized, parallel-
group trial was conducted from April to October 2003 
  according to the Declaration of Helsinki and Good Clinical 
Practice at 24 trial centers in 9 European countries   (Belgium, 
France, Germany, Italy, Portugal, Spain, Sweden,   Switzerland, 
and the Netherlands). Trial protocol and amendments were 
approved by the corresponding independent Ethics Commit-
tees of each participating country; patients’ written informed 
consent was obtained at enrolment.
Prior to hand surgery, patients were randomly assigned in 
a 1:1 ratio to receive either tramadol/paracetamol tablets plus 
placebo capsules or tramadol capsules plus placebo tablets 
(double-dummy design). Placebo capsules and tablets were 
identical in size and appearance to the active medication. 
Computer-generated lists for blockwise randomization fol-
lowing the treatment allocation ratio of 1:1 were prepared by 
an independent clinical research organization (M.A.R.C.O., 
Düsseldorf, Germany) and block size was given in the 
  randomization list but not to the investigators; investigators 
and patients were blinded to the treatment.
Surgical procedures were carried out as ambulatory 
  surgery. Patients received 1 to 3 mg midazolam intravenously 
as premedication. Intravenous regional anesthesia was per-
formed as follows: a canula was inserted in the dorsum of 
the hand on the side to be operated on. An inflatable double-
cuff tourniquet with padding was applied to the upper arm. 
A tight elastic bandage was wrapped from distal to proximal 
while the arm was elevated. Alternatively, if the bandaging Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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was too painful for the subject to tolerate, the arm could be 
elevated for 3 minutes. The distal cuff was first inflated fol-
lowed by the proximal cuff. The distal cuff was then deflated. 
The cuffs were inflated to 100 mmHg above the subject’s 
systolic pressure (pulse occlusion could be determined by 
oximeter). Next, the bandage was removed and the absence 
of a pulse was confirmed. A local anesthetic (lidocaine 3 mg/
kg or   prilocaine 3 mg/kg) was injected using the dorsal 
hand canula. The injection was performed slowly at a rate 
of approximately 0.5 mL/sec. If the compression by the 
proximal cuff caused pain during surgery, the distal cuff was 
inflated followed by deflation of the proximal cuff.
Independently of the duration of surgery, the double-cuff 
tourniquet was to remain inflated for at least 20 minutes after 
the injection. The maximum time of inflation should not 
exceed 90 minutes. The subject was observed and vital signs 
were recorded immediately before and for 10 minutes after 
deflation of the tourniquet. Sedation was assessed before the 
second measurement of the vital signs. Intraoperative seda-
tion with midazolam was allowed but the total dose, including 
pre-medication, should not exceed 7.5 mg.
The trial included a surgery day and a postoperative day. 
Upon discharge on surgery day, patients were given a diary 
to document their efficacy and safety evaluations at home. 
On the second postoperative day, patients visited the center 
for final assessments and returned the diary. Trial medication 
(1 active unit plus 1 placebo unit) was first administered at 
admission; a second dose was given in the recovery room 
after assessment of vital signs and sedation 10 minutes after 
deflation of the tourniquet. At home, patients took 1 unit of 
active plus 1 unit of placebo trial medication every 6 hours 
(except at nighttime if not required); an additional unit could 
be taken in case of insufficient analgesia (earliest 30 minutes 
after the regular dose). The maximum permitted daily dose 
was 8 tablets/capsules of active medication. Patients were 
instructed not to take any trial medication after midnight of 
the first postoperative day. No other analgesic medication 
was permitted. If the patient wished to discontinue the trial 
medication owing to an adverse event or lack of efficacy, 
diclofenac 50 mg (not exceeding 150 mg daily) could be 
used as rescue medication.
Outcome variables
Pain intensity was assessed by the patient after surgery 
(10 minutes after deflation of the tourniquet). Further effi-
cacy assessments were performed by the patient at home 
and recorded in a diary on the evenings of the surgery and 
the first postoperative day. All entries were to be completed 
before midnight of the first postoperative day; information 
on treatment response and pain intensity was to be recorded 
immediately before bedtime.
The primary efficacy variable was the rate of patients 
responding to treatment based on treatment satisfaction as 
recorded on the evening of the first postoperative day using 
a 4-point verbal rating scale (0 = poor, 1 = fair, 2 = good, 
3 = excellent). A patient was defined as a responder with 
a rating of 2 or 3 and no intake of rescue medication or 
other concomitant analgesia before midnight of the first 
  postoperative day.
Secondary efficacy variables included the assessment of 
the patient’s average pain intensity over the last 24 hours 
for surgery and first postoperative day on an 11-point 
numerical rating scale (from 0 = no pain to 10 = worst 
imaginable pain), time to first intake and total intake of trial 
medication at home, time to discontinuation and premature 
discontinuation rate owing to lack of efficacy, time to first 
intake and total intake of rescue medication, and total 
intake of antiemetic medication. For premature discontinu-
ation due to lack of efficacy, intake of rescue medication 
or any other analgesic medication was taken as time point 
of termination.
Safety evaluations by the investigator included adverse 
events (AEs) documentation and sedation assessment after 
surgery (10 minutes after deflation of the tourniquet) and 
before discharge, and vital signs (pulse and respiratory 
rate, and systolic and diastolic blood pressure) at admission, 
immediately before and 10 minutes after tourniquet   deflation, 
and before discharge. AEs were also recorded by the patients. 
Additionally, premature discontinuation owing to AEs and 
the time to this event were documented.
statistical analysis
In order to detect a difference in response rates (based on 
the patients’ treatment satisfaction) of at least 20% between 
the two treatment groups and assuming a 50% response 
rate for tramadol, it was determined that a sample size of 
116 patients per group was required to achieve an appropri-
ate statistical power of 85%. Taking a 10% drop-out rate 
into account, a total of 258 patients was required in order to 
obtain 232 patients completing the trial.
Efficacy was analyzed using the full analysis set (FAS) 
which included all randomized patients who received at least 
1 dose of trial medication and provided information with 
respect to the primary efficacy variable. A per-protocol (PP) 
analysis including all FAS patients without major protocol 
violations was used for sensitivity analysis.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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All statistical tests were performed as 2-sided tests 
with a significance level of 5 unless otherwise specified. 
All statistical analysis was done with pooled centers, 
the exception being the primary variable which was also 
evaluated per   center. Response rates were analyzed using a 
Cochran–Mantel–Haenszel (CMH) test adjusting for center; 
the interaction of treatment and center was checked by a 
Breslow–Day test for homogeneity. The difference between 
treatment groups was calculated using the associated 2-sided 
95% confidence interval (CI). Treatment differences were 
considered significant at P , 0.05. The primary analysis was 
the only confirmatory analysis; all secondary analyses were 
exploratory. Treatment differences for the parameter pain 
intensity as assessed after surgery were analyzed by means 
of an analysis of variance including effects for treatment, 
center, and treatment and center interaction. A separate 
analysis of variance was carried out for the assessment by 
the patients at home. A stratified Cox proportional hazards 
model using treatment as factor and center as stratum was 
applied for the analyses of time to premature trial discon-
tinuation due to AEs and due to lack of efficacy. The last 
observation carried forward approach was used only for the 
assessment of the primary variable, the secondary efficacy 
variable pain intensity, and the safety variable sedation. 
If the patient’s assessment of the primary variable for the 
first postoperative day was missing, the assessment on the 
evening of surgery day was used. If the assessment from 
the operative day was also missing, this value was replaced 
by ‘poor’.
All patients receiving at least 1 dose of trial medication 
were included in the descriptive safety analysis. Adverse 
events were encoded using the Medical Dictionary for 
  Regulatory Activities (MedDRA) version 6.0.
All statistical analyses were performed with SAS version 
8.2 (SAS Institute, Cary, NC, USA).
Results
A total of 132 patients received tramadol/paracetamol com-
bination treatment, and 129 patients took tramadol. The 
majority completed the trial (83.5%); reasons for premature 
withdrawal were lack of efficacy, AEs, or protocol   violations 
(Figure 1).
Most patients (98%) were included in the primary FAS 
analysis; 39 of those (21 in the tramadol, 18 in the tramadol/
paracetamol group) were excluded from the PP analysis 
(n = 217) due to violations of the study protocol. Baseline 
characteristics and surgery details were comparable between 
both groups (FAS population; Table 1). More females than 
males participated; except for 4 tramadol-treated patients, 
the trial population was of Caucasian origin.
Efficacy outcomes
Treatment satisfaction
A larger proportion of FAS patients in the tramadol/ 
paracetamol group (78.1% vs 71.9% in the tramadol group) 
were considered treatment responders at the end of the first 
postoperative day (primary efficacy variable). The estimated 
difference in response rate of 6.25% (95% CI [−4.3, 16.8]; 
P = 0.24 [CMH test]) in favor of tramadol/paracetamol 
treatment was, however, statistically not significant. The 
PP analysis confirmed the finding (83.6% vs 75.7%), with 
an estimated difference of 7.94% (tramadol/paracetamol vs 
tramadol; 95% CI [−2.7, 18.6]; P = 0.13 [CMH test]).
Treatment satisfaction was also recorded as at least good 
in more patients on combination therapy (77.3% vs 71.9% on 
tramadol treatment) for the day of surgery (Figure 2); again 
differences were not significant.
Pain intensity
Pain intensity was comparable for both treatments. 
Ten   minutes after deflation of the tourniquet, mean pain 
Full analysis set
N = 128
Excluded n = 4 (response
not assessable) 
Patients randomized 
N = 261
Full analysis set
N = 128
Excluded n = 1 (response 
not assessable)
Trial completers N = 109
Premature discontinuation N = 23
Lack of efficacy n = 17
Protocol violation n = 7
Adverse event n = 6
Trial completers N = 109
Premature discontinuation N = 20
Lack of efficacy n = 14
Protocol violation n = 3
Adverse event n = 8
Patients enrolled 
N = 261
Tramadol HCL 50 mg
N = 129 
Tramadol HCL 37.5 mg
Paracetamol 325 mg
N = 132
Figure 1 CONSORT flow chart.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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  intensity was 2.7 ± 2.2 for patients on tramadol/paracetamol 
and 2.9 ± 2.6 for patients treated with tramadol, and remained 
on a similar mean score on the evening of surgery day 
(2.6 ± 2.2 vs 2.8 ± 2.2; ANOVA P = 0.47). A total of 71.9% 
of tramadol/paracetamol and 64.1% of tramadol patients 
rated pain intensity with a score of #3 on the 11-point NRS 
on the evening of surgery day. The proportion of patients 
with this score increased to 83.6% of tramadol/paracetamol 
and 81.3% of tramadol patients in the evening of the first 
postoperative day which corresponded to mean scores of 
1.7 ± 2.0 for both groups (ANOVA P = 0.61). The proportion 
of patients experiencing no pain (score = 0) on the evening 
of the first postoperative day had markedly increased from 
surgery day: 16.4% to 35.9% for tramadol/paracetamol, 18% 
to 36.7% for tramadol treatment.
Further assessments
Table 2 lists further assessment outcomes. The intake of trial 
medication was comparable for the treatment groups; 80.5% 
in the tramadol/paracetamol and 82% in the tramadol group 
reported a total intake of 4 to 8 tablets or capsules. In total, the 
group on combination treatment received 29.55 g of tramadol, 
whereas the group on tramadol monotherapy received 38.8 g. 
This amounts to a reduction in tramadol intake of 23.8% using 
combination treatment. Time to first intake of trial medication 
was also comparable between the treatment groups.
Table 1 Baseline characteristics and surgery details of the trial 
population (full analysis set)
Tramadol/
paracetamol 
(n = 128)
Tramadol 
(n = 128)
gender, male/female (%) 41.4/58.6 35.9/64.1
Age (years) 46.2 ± 13.4 47.6 ± 12.9
Body mass index (kg/m2) 26.3 ± 4.8 26.4 ± 5.3
Surgery details
Type of hand surgery
  Bony 21 (16.4%) 21 (16.4%)
  Ligamentous 107 (83.6%) 107 (83.6%)
Dose of local anesthesia during surgery
  Lidocaine
    Total 198.4 ± 55.6 199.6 ± 81.2
    Per kg body weight 2.7 ± 0.6 2.7 ± 1.2
  Prilocaine
    Total 285.0 ± 89.3 272.1 ± 93.2
    Per kg body weight 4.0 ± 1.5 3.7 ± 1.3
Duration of surgery (min) 26.1 ± 14.4 24.8 ± 14.4
Duration of tourniquet inflation (min) 44.5 ± 15.6 43.8 ± 16.7
Total dose of midazolam (mg) 3.1 ± 1.8 3.2 ± 2.0
Pain intensity 10 min after tourniquet 
deflation
2.7 ± 2.2 2.9 ± 2.6
Note: Data are mean ± sD or number of patients (%).
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Figure 2 Treatment satisfaction as recorded by the trial population on the evening 
of  surgery  and  of  the  first  postoperative  day  (full  analysis  set).  ()  tramadol/
paracetamol combination therapy, () tramadol monotherapy.
Table 2 Additional secondary efficacy outcomes (full analysis set)
Tramadol/
paracetamol 
(n = 128)
Tramadol 
(n = 128)
number of tablets/capsules taken
  ≤2 4 (3.1%) 5 (3.9%)
 3 12 (9.4%) 9 (7%)
 4 11 (8.6%) 17 (13.3%)
 5 12 (9.4%) 14 (10.9%)
 6 29 (22.7%) 29 (22.7%)
 7 41 (32%) 31 (24.2%)
 8 10 (7.8%) 14 (10.9%)
  .8 9 (7%) 9 (7%)
Time to first intake of trial 
medication (h)
6.59 ± 1.82 6.73 ± 2.04
Rescue medication (diclofenac 50 mg) 22 (17.2%) 17 (13.3%)
Time to first intake of rescue 
medication (h)
25.6 ± 20.8 25.6 ± 20.0
Antiemetic medication 
(metoclopramide)
21 (16.4%) 28 (21.9%)
Premature withdrawal due to lack  
of efficacy
17 (13.3%) 14 (10.9%)
Time to premature withdrawal due  
to lack of efficacy (h)
12.8 ± 11.3 10.2 ± 9.0
Note: Data are mean ± sD or number of patients (%).Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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More patients on combination therapy (17.2% vs 13.3% 
for monotherapy) used rescue medication; the difference was, 
however, not significant. There were also no significant dif-
ferences between treatments for any of the other secondary 
efficacy variables.
safety outcomes
The incidence of treatment-emergent AEs differed signifi-
cantly between the groups: 54 (40.9%) patients on tramadol/
paracetamol reported 130 AEs whereas 74 (57.4%) trama-
dol patients experienced 193 AEs (explorative P = 0.0041; 
  difference: −16.5% [95% CI: −28.4, −4.5]). Most AEs were 
mild to moderate in intensity. Fourteen and 17 AEs of severe 
intensity were observed in patients receiving combination 
therapy and patients on tramadol, respectively, mostly 
nausea, vomiting and dizziness. Table 3 lists all AEs with 
a frequency of at least 5% in either group.
Nausea was the most common event in both groups (25.8% 
for tramadol/paracetamol vs 36.4% for tramadol)   followed by 
dizziness (15.9% vs 18.6%) and somnolence (9.1% vs 14%). 
Overall, incidences were lower in the tramadol/paracetamol 
group for gastrointestinal disorders (28.8% vs 44.2% for 
tramadol) and nervous system disorders (21.2% vs 32.6%). For 
combination treatment, 110 (84.6%) of the AEs were considered 
at least possibly related to the trial medication; the corresponding 
numbers for tramadol monotherapy were 170 (88.1%).
One 19-year-old female receiving tramadol/  paracetamol 
experienced 2 serious AEs of severe intensity (nausea and 
hypotension) 3.5 hours after intake of trial medication leading 
to hospitalization for 1 night. Both events resolved within the 
next day. The patient continued taking the trial medication.
Six (4.5%) patients receiving tramadol/paracetamol and 
8 (6.2%) patients on tramadol prematurely withdrew owing 
to AEs; the most common reasons were gastrointestinal 
complaints. Time to premature discontinuation due to AEs 
was calculated for the FAS population and similar for both 
treatments: 12.1 ± 9.5 hours for tramadol/paracetamol and 
11.5 ± 9.5 hours for tramadol (Table 3).
There were no differences between treatments regarding 
vital signs and sedation assessment. Ten minutes after deflation 
of the tourniquet, the majority of patients in both groups were 
awake and spontaneous communication was possible (93.8% 
for tramadol/paracetamol, 91.4% for tramadol; FAS).
Discussion
This randomized, double-blind, multicenter trial demon-
strated that postoperative pain following ambulatory hand 
surgery was effectively managed in the majority of patients 
by tramadol 37.5 mg/paracetamol 325 mg combination treat-
ment with no statistically significant differences in efficacy 
to tramadol 50 mg monotherapy but with fewer AEs.
Intake of tramadol/paracetamol combination tablets before 
and immediately after surgery and every 6 hours thereafter 
markedly reduced pain intensity from surgery day by the end 
of the first postoperative day. A pain intensity score #3 (on a 
numerical rating scale up to 10 for ‘worst imaginable pain’) was 
reported by 84% of these patients and the number of patients 
experiencing no pain (score = 0) more than doubled from 16% 
on the day of surgery to 36% on the first postoperative day. 
Accordingly, treatment satisfaction was high; 78% were con-
sidered treatment responders based on their satisfaction with 
the medication. Good efficacy was also confirmed by the low 
proportion of patients resorting to rescue medication and the 
low premature withdrawal rate owing to a lack of efficacy.
Most of the published literature on efficacy of the combi-
nation tablet in the management of postoperative pain report 
the outcome of single-dose treatment for moderate to severe 
dental pain.12,27–29 In a meta-analysis of 5 randomized, double-
blind, placebo-controlled trials the number-needed-to-treat 
(NNT) to achieve at least 50% pain relief over 6 hours was 
2.6 for tramadol 75 mg/paracetamol 650 mg, which was 
superior to an NNT of 9.9 for tramadol 75 mg, and 3.6 
for   paracetamol 650 mg.12   Relative benefits of the three 
  single-dose analgesic treatments were similar when pooled 
Table 3 summary of treatment-emergent adverse events (safety 
population)
Tramadol/
paracetamol 
(n = 132)
Tramadol 
(n = 129)
Any adverse event 54 (40.9%) 74 (57.4%)
Any severe adverse event 8 (6.1%) 7 (5.4%)
Any serious adverse event 1 (0.8%) 0
Any drug-related adverse eventa
  Possible relationship 29 (22%) 51 (39.5%)
  Probable/likely relationship 24 (18.2%) 29 (22.5%)
  certain relationship 1 (0.8%) 5 (3.9%)
Any adverse event causing premature 
discontinuation from trial
6 (4.5%) 8 (6.2%)
Time to premature withdrawal due  
to adverse event (h)b
12.1 ± 9.5 11.5 ± 9.5
Any adverse event ≥5% incidence  
in either groupc
  nausea 34 (25.8%) 47 (36.4%)
  Dizziness 21 (15.9%) 24 (18.6%)
  somnolence 12 (9.1%) 18 (14.0%)
  Vomiting 9 (6.8%) 16 (12.4%)
  sweating increased 6 (4.5%) 9 (7.0%)
Note: Data are number of patients (%).  aPatients can appear in all 3 categories; 
bcalculated  for  full  analysis  set;  cListed  in  order  of  decreasing  frequency  in  the 
tramadol/paracetamol group.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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data from   gynecological and orthopedic procedures were 
  analyzed.12 Efficacy of multiple tramadol 37.5 mg/  paracetamol 
325 mg doses proved superior to placebo following abdominal 
or orthopedic inpatient surgery and pain relief was similar 
to the combination of codeine 60 mg/paracetamol 600 mg 
during the immediate   postoperative period.13
In the present trial, analgesic efficacy of the two treatments 
was comparable but multiple-dose tramadol/  paracetamol 
treatment showed a better safety profile than tramadol mono-
therapy. This is in line with a short-term (10 days) treatment 
trial in patients with subacute low back pain which reported 
significantly fewer AEs under combination therapy.17 In the 
present trial, the overall incidence of AEs was markedly lower 
in the combination group with significantly fewer patients 
reporting AEs. The majority of AEs in both groups were 
side-effects usually associated with tramadol such as nausea, 
dizziness, somnolence,   vomiting, and increased sweating.10 
Gastrointestinal and nervous system disorders were reported 
with a 15.4% and 11.4% lower frequency, respectively, for 
tramadol/paracetamol treatment.
The difference in tolerability might thus be attributed 
to the reduced intake of tramadol in the combination group 
which was 23.8% less than in patients receiving tramadol 
monotherapy. Tramadol-sparing did not lower the analgesic 
efficacy of the combination tablet, probably owing to the 
individual compounds acting additively.8,9
In summary, tramadol/paracetamol combination tablets 
provided comparable analgesic efficacy to tramadol capsules, 
with fewer AEs, in patients experiencing postoperative pain 
following ambulatory hand surgery.
List of study investigators
Belgium: V Macquaire, E Spyropoulos; France: A   Babinet, 
RP Bleton, P Catoire, M Chauvin, L Delaunay, E   Gaertner, 
L Le Gourrier, R Lepescu, C Menigaux, B Toussaint;   Germany: 
W Bannasch, R Finck, J Freier, D Petermeise, E Pinkowski, R 
Pinkowski; Italy: M Berti, M Montebugnoli; Portugal: R Costa, 
C da Silva João, N Dias, P Lemos, D Marques, MF Martins 
Nunes, JC Parreira; Spain: E Catalá, E Concha, J de Andrés, 
FJ González-Carrasco, A Garcia-Muret, D Román, LM Torres; 
Sweden: H Alnehill, A Amilon, N Rawal; Switzerland: 
G Schüpfer, M Wietlisbach, S Zbinden; The Netherlands: 
HPM Renkens, E van Ark, RL van Leersum.
Acknowledgments
The authors would like to thank all participating investiga-
tors. The trial was sponsored by Grünenthal GmbH, Aachen, 
Germany. Editorial assistance and publication coordination 
were provided by E. Grosselindemann and B. Brett (Brett 
Medical Writing). All associated costs were met by the 
sponsor of the trial.
Disclosure
NR has received honoraria and speaker fees from Baxter, 
Nycomed, Vygon, Sintetica, and MSD. EC has received 
speaker fees from Grünenthal. All other authors have   nothing 
to declare.
References
  1.  Aylin P, Williams S, Jarman B, Bottle A. Trends in day surgery rates. 
BMJ. 2005;331:803.
  2.  Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United 
States, 2006. National Health Statistics Reports 2009. http://www.cdc.
gov/nchs/products/nhsr.htm. Accessed November 10, 2010.
  3.  Rawal N. Analgesia for day-case surgery. Br J Anaesth. 2001;87:73–87.
  4.  Chung F, Ritchie E, Su J. Postoperative pain in ambulatory surgery. 
Anesth Analg. 1997;85:808–816.
  5.  Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the 
hospital following ambulatory surgery. JAMA. 1989;262:3008–3010.
  6.  Rawal N, Hylander J, Nydahl P-A, Olofsson I, Gupta A. Survey of post-
operative analgesia following ambulatory surgery. Acta Anaesthesiol 
Scand. 1997;41:1017–1022.
  7.  Beauregard L, Pomp A, Choinière M. Severity and impact of pain after 
day-surgery. Can J Anaesth. 1998;45:304–311.
  8.  Raffa RB. Pharmacology of oral combination analgesics: rational 
therapy for pain. J Clin Pharm Ther. 2001;26:257–264.
  9.  Desmeules J, Rollason V , Piguet V , Dayer P. Clinical pharmacology and 
rationale of analgesic combinations. Eur J Anaesthesiol. 2003; 20(Suppl 
28):7–12.
  10.  Scott LJ, Perry CM. Tramadol. A review of its use in perioperative pain. 
Drugs. 2000;60:39–176.
  11.  Parfitt K, editor. Analgesics, anti-inflammatory drugs and antipyretics. 
In: Martindale, The Complete Drug Reference, 32nd edition. London, 
UK: Pharmaceutical Press; 1999:1–91.
  12.  Edwards JE, McQuay HJ, Moore RA. Combination analgesic efficacy: 
individual patient data meta-analysis of single-dose oral tramadol plus 
acetaminophen in acute postoperative pain. J Pain Symptom Manage. 
2002;23:121–130.
  13.  Smith AB, Ravikumar TS, Kamin M, Jordan D, Xiang J, Rosenthal N, 
on behalf of the CAPSS-115 Study Group. Combination tramadol plus 
acetaminophen for postsurgical pain. Am J Surg. 2004;187:521–527.
  14.  Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acet-
aminophen combination tablets in the treatment of fibromyalgia pain: 
a double-blind, randomized, placebo-controlled study. Am J Med. 
2003;114:537–545.
  15.  Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M, on behalf of the 
Protocol CAPSS-112 Study Group. Tramadol/acetaminophen combina-
tion tablets for the treatment of chronic lower back pain: a multicenter, 
randomized, double-blind, placebo-controlled outpatient study. Clin 
Ther. 2003;25:1123–1141.
  16.  Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal NR on behalf of 
the Protocol TRP-CAN-1 Study Group. Analgesic efficacy and safety 
of tramadol/acetaminophen combination tablets (Ultracet®) in treatment 
of chronic low back pain: a multicenter, outpatient, randomized, double 
blind, placebo controlled trial. J Rheumatol. 2004;31:2454–2463.
  17.  Perrot S, Krause D, Crozes P, Naïm C, for the GRTF-ZAL-1 Study Group. 
Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) 
combination treatment compared with tramadol (50 mg) monotherapy 
in patients with subacute low back pain: a   multicenter, randomized, 
double-blind, parallel-group, 10-day treatment study. Clin Ther. 
2006;28:1592–1606.Journal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
110
Rawal et al
  18.  Silberstein SD, Freitag FG, Rozen TD, Kudrow DB, Hewitt DJ, 
Jordan DM, et al. Tramadol/acetaminophen for the treatment of acute 
migraine pain: findings of a randomized, placebo-controlled trial. 
Headache. 2005;45:1317–1327.
  19.  Silverfield JC, Kamin M, Wu SC, Rosenthal N, for the CAPSS-105 
Study Group. Tramadol/acetaminophen combination tablets for the 
treatment of osteoarthritis flare pain: a multicenter, outpatient, random-
ized, double-blind, placebo-controlled, parallel-group, add-on study. 
Clin Ther. 2002;24:282–297.
  20.  Lee EY, Lee EB, Park BJ, Lee CK, Yoo B, Lim MK, et al. Tramadol 
37.5-mg/acetaminophen 325-mg combination tablets added to regular 
therapy for rheumatoid arthritis pain: a 1-week, randomized, double-
blind, placebo-controlled trial. Clin Ther. 2006;28:2052–2060.
  21.  Dhillon S. Tramadol/paracetamol fixed-dose combination. A review 
of its use in the management of moderate to severe pain. Clin Drug 
Investig. 2010;30:711–738.
  22.  Ko SH, Kwon HS, Yu JM, Baik SH, Park IB, Lee JH, et al. Comparison 
of the efficacy and safety of tramadol/acetaminophen combination 
therapy and gabapentin in the treatment of painful diabetic neuropathy. 
Diabet Med. 2010;27:1033–1040.
  23.  Brull TR, von Schroeder H, Anastakis D, Graham B, Katz J, Chan VWS, 
et al. Regional anesthesia versus general anesthesia for ambulatory hand 
surgery. Reg Anesth Pain Med. 2003;28:A1(abstract).
  24.  Pregler JL, Kapur PA. The development of ambulatory anesthesia 
and future challenges. Anesthesiol Clin North America. 2003;21: 
207–228.
  25.  Rawal N, Allvin R, Amilon A, Ohlsson T, Hallén J. Postoperative anal-
gesia at home after ambulatory hand surgery: a controlled comparison 
of tramadol, metamizol, and paracetamol. Anesth Analg. 2001;92: 
347–351.
  26.  Camporesi EM, Greeley WJ, Lumb PD, Watkins WD. Anesthesia. In: 
Sabiston DC Jr, editor. Textbook of Surgery. WB Saunders Company; 
1991:148–163.
  27.  Fricke JR, Karim R, Jordan D, Rosenthal N. A double-blind, single-
dose comparison of the analgesic efficacy of tramadol/acetaminophen 
combination tablets, hydrocodone/acetaminophen combination tablets, 
and placebo after oral surgery. Clin Ther. 2002;24:953–968.
  28.  Fricke JR, Hewitt DJ, Jordan DM, Fisher A, Rosenthal NR. A double-
blind placebo-controlled comparison of tramadol/acetaminophen and 
tramadol in patients with postoperative dental pain. Pain. 2004;109: 
250–257.
  29.  Jung Y-S, Kim DK, Kim M-K, Kim H-J, Cha I-H, Lee E-W. Onset 
of analgesia and analgesic efficacy of tramadol/acetaminophen and 
codeine/acetaminophen/ibuprofen in acute postoperative pain: a single-
center, single-dose, randomized, active-controlled, parallel-group study 
in a dental surgery pain model. Clin Ther. 2004;26:1037–1045.